Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$7.44 - $10.65 $1,733 - $2,481
-233 Closed
0 $0
Q1 2018

Apr 20, 2018

SELL
$9.53 - $15.68 $3,354 - $5,519
-352 Reduced 60.17%
233 $2,000
Q3 2017

Oct 27, 2017

SELL
$13.06 - $19.67 $13 - $19
-1 Reduced 0.17%
585 $12,000
Q2 2017

Aug 14, 2017

BUY
N/A
586
586 $9,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $338M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Cable Hill Partners, LLC Portfolio

Follow Cable Hill Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cable Hill Partners, LLC with notifications on news.